Bristol-Myers Squibb
BMY
BMY
2,372 hedge funds and large institutions have $91B invested in Bristol-Myers Squibb in 2023 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 774 increasing their positions, 1,182 reducing their positions, and 180 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
2,372
Holders Change
-92
Holders Change %
-3.73%
% of All Funds
37.82%
Holding in Top 10
42
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-4.55%
% of All Funds
0.67%
New
118
Increased
774
Reduced
1,182
Closed
180
Calls
$2.31B
Puts
$1.8B
Net Calls
+$506M
Net Calls Change
+$74.6M
Top Buyers
| 1 |
Two Sigma Advisers
New York
|
$384M |
| 2 |
Jane Street
New York
|
$208M |
| 3 |
D.E. Shaw & Co
New York
|
$211M |
| 4 |
IFP
Independent Franchise Partners
London,
United Kingdom
|
$856M |
| 5 |
Morgan Stanley
New York
|
$2.13B |
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
$5.61B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
$11.6B |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
$2.5B |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
$659M |
| 5 |
State Street
Boston,
Massachusetts
|
$5.19B |